Effect of Gundelia tournefortii on Coronary Heart Disease

Effect of Gundelia tournefortii extracts on Plasminogen Activator Inhibitor-1, Thromboxane B2, Lipid Profile, Antioxidant Capacity in Patients with Coronary Artery Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013102311288N6

Enrollment

Registered

2014-02-11

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease. Atherosclerotic Heart Disease

Interventions

Intervention 1: Intervention group:Consumption of Gundelia tournefortii extracts equivalent 6 gr Gundelia tournefortii (500 mg capsules one time a day). Intervention 2: Placebo group: Consumption of s

Treatment - Drugs

Placebo

Intervention group:Consumption of Gundelia tournefortii extracts equivalent 6 gr Gundelia tournefortii (500 mg capsules one time a day)

Placebo group: Consumption of starch(500 mg capsules one time a day)

Eligibility

Sex/Gender

Male

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:angiographically confirmed coronary artery disease with more than 50% stenosis of at least one of the major coronary vessels; subjects with 30-60 years old; BMI equal 20-30 kg/m2 exclusion criteria:Myocardial infarction, heart failure, heart valve disease, myocardial inflammation, stress and severe inflammation, smoking, more than 8 hours per week of vigorous exercise, diabetes, immunosuppressive drugs, anti-inflammatory and antioxidant vitamin supplements and herbal medicine, weight loss drugs or weight loss surgery.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Antioxidant Capacity. Timepoint: Beginning and the end of the intervention. Method of measurement: Special kits.;Plasminogen Activator Inhibitor-1. Timepoint: Beginning and the end of the intervention. Method of measurement: Special kits.;Thromboxane B2. Timepoint: Beginning and the end of the intervention. Method of measurement: Special kits.;Lipid Profile. Timepoint: Beginning and the end of the intervention. Method of measurement: TC,TG,HDL-C,LDL-C mesearment with special kits.	—

Measure

Time frame

Antioxidant Capacity. Timepoint: Beginning and the end of the intervention. Method of measurement: Special kits.;Plasminogen Activator Inhibitor-1. Timepoint: Beginning and the end of the intervention. Method of measurement: Special kits.;Thromboxane B2. Timepoint: Beginning and the end of the intervention. Method of measurement: Special kits.;Lipid Profile. Timepoint: Beginning and the end of the intervention. Method of measurement: TC,TG,HDL-C,LDL-C mesearment with special kits.

—

Secondary

Measure	Time frame
Blood Pressure. Timepoint: Beginning and the end of the intervention. Method of measurement: Standard Sphygmomanometer.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026